This website uses cookies to improve your experience. Learn more about cookies and how to manage them.

Society news and updates

COVID-19 news

  • Clinical pharmacologists to advise on national COVID-19 trials. Read more
  • Society endorses new advisory group providing guidance on use of medicines for COVID-19. Read more
  • The Society publishes position on animal models and COVID-19. Read more
  • Read our blog about our policy and research dissemination priorities during this time
  • The Society publishes positions on medicines use and development relating to COVID-19. Read more
  • Important message about the impact of the coronavirus pandemic on the Society's activities. Read more
  • An update on the impact of the novel coronavirus (COVID-19) outbreak on Society meetings and events. Read more
  • ‚ÄčAll published articles relevant for COVID-19 in the British Journal of Pharmacology and the British Journal of Clinical Pharmacology have been, or will be, made free to access immediately.  For the latest information on the call for papers, visit our how you can help page.

Policy statements

  • The Society and ASCEPT publish clinical pharmacology principles for use in the development of safe and efficacious COVID-19 treatments. Read more
  • The Society outlines why development of valid animal models will help identify safe and effective treatments for COVID-19. Read more
  • The Society responds to government recovery strategy. Read more 
  • The Society responds to a new roadmap for identifying COVID-19 treatments. Read more
  • The Society advocates that approval of treatments for COVID-19 be expedited safely. Read more
  • The Society sets out why standards and guidance for clinical research relating to COVID-19 are urgently needed to ensure trial data are meaningful. Read more
  • The Society outlines why comprehensive pharmacovigilance and pharmacoepidemiology are needed to inform medication use during the COVID-19 pandemic. Read more
  • The Society has responded to the announcement that Gilead Sciences will initiate two phase 3 randomised studies to evaluate the safety and antiviral activity of remdesivir in participants with moderate to severe COVID-19.      Read more
  • The Society has responded to concerns that the use of non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, could make the symptoms of the novel coronavirus infection, COVID-19, worse. Read more 

Prescribing Safety Assessment news and updates

 
  • An update on medical school final examinations from the Medical Schools Council. Read more
  • Information and guidance on the delivery of the PSA 2020. Read more